Protective effect of recombinant human glucagon-like peptide-1 (rhGLP-1) pretreatment in STZ-induced diabetic mice

Journal of Peptide Science

Volumn 17, Issue 7, 2011, Pages 499-504

  Wu, Ye Lin ^a   Huang, Jing ^a   Liu, Jian ^a   Jin, Ming Fei ^a   Gu, Mei ^b   Hong, Yiguo ^b   Wu, Zi Rong ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Diabetes mellitus; GLP 1; Lipid peroxidation; Oxidative stress; Streptozotocin; Type 2 diabetes

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; RECOMBINANT GLUCAGON; RECOMBINANT HUMAN GLUCAGON LIKE PEPTIDE 1; STREPTOZOCIN; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BULIMIA; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG INDUCED DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; IN VIVO STUDY; LIPID PEROXIDATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET DISEASE; POLYDIPSIA; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; MICE; OXIDATIVE STRESS; PANCREAS; RECOMBINANT PROTEINS;

MUS;

EID: 79958810233     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1352     Document Type: Article

References (20)

1. Francesco G, Annalisa N, Anna L, Luigi L. Exploiting the pleiotropic actions of GLP-1 for the management of type 2 diabetes mellitus and its complications. Diabetes Res. Clin.Pract. 2007; 78: S59-S67.
2. Wang XY, Sun J, Wang C, France M, Sheil AG. Effect of liver transplantation on islet allografts: up-regulation of Fas ligand and apoptosis of T lymphocytes are associated with islet graft tolerance. Transplantation 2001; 71: 102-111.
3. Liu Q, El-Deiry WS, Gazitt Y. Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines. Exp. Hematol. 2001; 29: 962-970.
4. Li J, Huang CY, Zheng RL, Cui KR, Li JF. Hydrogen peroxide induces apoptosis in human hepatoma cells and alters cell redox status. Cell Biol. Int. 2000; 24: 9-23.
5. Matz PG, Copin JC, Chan PH. Cell death after exposure to subarachnoid hemolysate correlates inversely with expression of CuZn-superoxide dismutase. Stroke 2000; 31: 2450-2459.
6. Behme MT, Dupre J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr. Disord. 2003; 3: 3.
7. Qin Z, Sun Z, Huang J, Hu Y, Wu Z, Mei B. Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42). Neurosci. Lett. 2008; 444: 217-221.
8. Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003; 144: 1444-1455.
9. Zhang X, Zhu Z, Huang Z, Tan P, Ma RZ. Microsatellite genotyping for four expected inbred mouse strains from KM mice. J. Genet. Genomics 2007; 34: 214-222.
10. Wu YL, Huang J, Xu J, Liu J, Feng Z, Wang Y, Lai Y, Wu ZR. Addition of a cysteine to glucagon-like peptide-1 (GLP-1) conjugates GLP-1 to albumin in serum and prolongs GLP-1 action in vivo. Regul. Pept. 164: 83-89.
11. Nauck MA, Wollschlager D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996; 39: 1546-53.
12. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002; 51: 1443-1452.
13. Wang RN, Bouwens L, Kloppel G. Beta-cell growth in adolescent and adult rats treated with streptozotocin during the neonatal period. Diabetologia 1996; 39: 548-557.
14. Shirpoor A, Ansari MH, Salami S, Pakdel FG, Rasmi Y. Effect of vitamin E on oxidative stress status in small intestine of diabetic rat. World J. Gastroenterol. 2007; 13: 4340-4344.
15. Anwer T, Sharma M, Pillai KK, Haque SE, Alam MM, Zaman MS. Protective effect of bezafibrate on streptozotocin-induced oxidative stress and toxicity in rats. Toxicology 2007; 229: 165-172.
16. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res. 2001; 50: 537-546.
17. Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 2004; 47: 478-487.
18. Holst JJ, Deacon CF, Vilsboll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol. Med. 2008; 14: 161-168.
19. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab. Res. Rev. 2002; 18: 430-441.
20. Green BD, Lavery KS, Irwin N, O'Harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. J. Pharmacol. Exp. Ther. 2006; 318: 914-921.